These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 38299148

  • 1. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y, Sun X, Liu G, Li H, Yu M, Zhu Y.
    Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
    [Abstract] [Full Text] [Related]

  • 2. Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
    Wang Y, Song W, Feng C, Wu S, Qin Z, Liu T, Ye Y, Huang R, Xie Y, Tang Z, Wang Q, Li T.
    J Transl Med; 2024 Oct 04; 22(1):900. PubMed ID: 39367493
    [Abstract] [Full Text] [Related]

  • 3. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    Zhang J, Zhou Q, Xie K, Cheng L, Peng S, Xie R, Liu L, Zhang Y, Dong W, Han J, Huang M, Chen Y, Lin T, Huang J, Chen X.
    J Exp Clin Cancer Res; 2021 Jun 21; 40(1):203. PubMed ID: 34154613
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X, Wang P, Qiao Q, Jiang Y.
    BMC Cancer; 2021 May 31; 21(1):646. PubMed ID: 34059019
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
    Sun JX, Liu CQ, Xu JZ, An Y, Xu MY, Zhong XY, Zeng N, Ma SY, He HD, Zhang ZB, Wang SG, Xia QD.
    Front Immunol; 2022 May 31; 13():908068. PubMed ID: 35898492
    [Abstract] [Full Text] [Related]

  • 10. Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
    Wu Y, Xu Y, He S, Li Y, Feng N, Fan J, Gong Y, Li X, Zhou L.
    Heliyon; 2023 Mar 31; 9(3):e13707. PubMed ID: 36873531
    [Abstract] [Full Text] [Related]

  • 11. Androgen Receptor Transcriptionally Inhibits Programmed Death Ligand-1 Expression and Influences Immune Escape in Bladder Cancer.
    Sun A, Luo Y, Xiao W, Zhu Z, Yan H, Miao C, Zhang W, Bai P, Liu C, Yang D, Shao Z, Song J, Wu Z, Chen B, Xing J, Wang T.
    Lab Invest; 2023 Jul 31; 103(7):100148. PubMed ID: 37059268
    [Abstract] [Full Text] [Related]

  • 12. Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer.
    Xu W, Tang HJ, Anwaier A, Liu W, Tian X, Su J, Wei S, Qu Y, Zhang H, Ye D.
    Front Immunol; 2022 Jul 31; 13():909324. PubMed ID: 35898507
    [Abstract] [Full Text] [Related]

  • 13. Metabolic-associated signature and hub genes associated with immune microenvironment and prognosis in bladder cancer.
    Guo Y, Zheng Z, Mao S, Yang F, Wang R, Wang H, Liu J, Li C, Wang Q, Zhang W, Yao X, Liu S.
    Mol Carcinog; 2023 Feb 31; 62(2):185-199. PubMed ID: 36250643
    [Abstract] [Full Text] [Related]

  • 14. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
    Shen C, Bi Y, Chai W, Zhang Z, Yang S, Liu Y, Wu Z, Peng F, Fan Z, Hu H.
    BMC Med Genomics; 2023 Oct 26; 16(1):264. PubMed ID: 37880682
    [Abstract] [Full Text] [Related]

  • 15. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
    Xie T, Peng S, Liu S, Zheng M, Diao W, Ding M, Fu Y, Guo H, Zhao W, Zhuang J.
    Mol Cancer; 2024 Feb 10; 23(1):30. PubMed ID: 38341586
    [Abstract] [Full Text] [Related]

  • 16. Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer.
    Xu Y, Xia Z, Sun X, Wei B, Fu Y, Shi D, Zhu Y.
    Front Immunol; 2023 Feb 10; 14():1111319. PubMed ID: 36911676
    [Abstract] [Full Text] [Related]

  • 17. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
    Liu L, Hu J, Wang Y, Sun T, Zhou X, Li X, Ma F.
    Aging (Albany NY); 2020 Jun 22; 12(12):11967-11989. PubMed ID: 32570217
    [Abstract] [Full Text] [Related]

  • 18. The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
    Gu Y, Huang Q, Wang Y, Wang H, Xiang Z, Xu Y, Wang X, Liu W, Wang A.
    BMC Cancer; 2024 Apr 05; 24(1):420. PubMed ID: 38580922
    [Abstract] [Full Text] [Related]

  • 19. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C, Chai W, Han J, Zhang Z, Liu X, Yang S, Wang Y, Wang D, Wan F, Fan Z, Hu H.
    Front Immunol; 2023 Apr 05; 14():1213947. PubMed ID: 37965307
    [Abstract] [Full Text] [Related]

  • 20. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X.
    Front Immunol; 2021 Apr 05; 12():725223. PubMed ID: 34484235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.